Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III Thymitaq trial cleared to continue by DSMB

Jan. 30, 2004

Merck and Jerini to develop small molecule inhibitors for cancer

Jan. 30, 2004

New antitumor agents developed by RIKEN scientists

Jan. 30, 2004

Altana researchers present two novel series of PARP-1 inhibitors

Jan. 30, 2004

SU-11248 inhibits tumor growth and osteolysis in a human breast cancer bone metastasis model

Jan. 30, 2004

Cleveland Clinic and Ricerca to develop cobalamin-based anticancer compound

Jan. 30, 2004

Novel selective cytokine inhibitory drugs demonstrate enhanced antiangiogenic activity

Jan. 30, 2004

Genta clarifies Genasense agreement terms

Jan. 29, 2004

SuperGen completes rolling NDA for Orathecin

Jan. 29, 2004

First European named patient sales of Voraxaze

Jan. 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...